Cadila to make India's first indigenous antibody test kit: Health Minister

The anti-SARS-Cov-2 human lgG ELISA kit has the advantage of testing 90 samples together in a single run of 2.5 hours

Drug testing
So far, ELISA kits were being largely imported with focus of indigenous manufacturing largely towards real-time polymerase chain reaction
Vinay Umarji Ahmedabad
2 min read Last Updated : May 10 2020 | 11:40 PM IST
Cadila Healthcare Ltd. (Zydus Cadila) is set to make India's first indigenously developed anti-SARS-Cov-2 human IgG ELISA test kit for antibody detection of Covid-19 (novel coronavirus), Union health minister Harsh Vardhan said in a tweet on Sunday.
Developed by National Institute of Virology (NIV), Pune, the robust test will play "a critical role in surveillance of proportion of population exposed to SARSCoV2 infection", the minister said.

"ELISA based testing is easily possible even at district level. The NIV Pune technology has been transferred to Zydus Cadila for mass-scale production. The Drug Controller General has granted commercial production & marketing permission to Zydus," Vardhan further said in his tweet. An email query sent to the company remained unanswered.

This kit was validated at two sites in Mumbai and has high sensitivity and accuracy. 

The anti-SARS-Cov-2 human lgG ELISA kit has the advantage of testing 90 samples together in a single run of 2.5 hours, so that healthcare professionals can proceed quickly with necessary next steps on their patients’ triage paths.

So far, ELISA kits were being largely imported with focus of indigenous manufacturing largely towards real-time polymerase chain reaction (RT-PCR) test kits which takes up to eight hours to give results.

Meanwhile, Zydus Cadila has been involved in developing a vaccine for Covid-19 with the company already hosting animal trial phase and hoping to take it to clinical trials in the coming months.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusLockdownCadila Healthcare Zydus CadilaHealth MinistryHarsh Vardhan

Next Story